TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Reduction of Port Wine Stain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Absorption of fluid through the gut
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in plaque from baseline to 4 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in plaque from baseline to 8 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative postoperative narcotic use
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of Participants With Major Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Length of stay in the hospital after surgery
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Time to Local Failure
Endpoint domain: Mortality/survival
Primary endpoint: Number of participants with spontaneous preterm birth rate < 37 weeks gestation
Endpoint domain: Mortality/survival
Primary endpoint: Number of participants with spontaneous preterm birth <34 weeks gestation
Endpoint domain: Mortality/survival
Primary endpoint: Local skin pressure while wearing a socket
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Skin surface temperature difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Gait parameter asymmetry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Socket evaluation questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Pulse Wave Velocity (PWVao)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from baseline in bladder volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change from baseline of detrusor pressure amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Mean change in carotid intima-media thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: %MetHb
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in the Distribution of Fecal Microbiota
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Alcohol Consumption in Drinks/Week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Hepatitis C Virus Ribonucleic Acid (HCV-RNA) Negative Participants at End of Therapy (EoT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of Participants With Early Virologic Response (EVR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of Participants With Sustained Virologic Response (SVR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Dose-limiting toxicity (DLT) rates
Endpoint domain: Adverse events/effects
Primary endpoint: % patients with RNA-HCV negative
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Intravascular ultrasound (IVUS) measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: oxygenated hemoglobin (O2HB)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: deoxygenated hemoglobin (HHB)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: blood oxygen saturation (O2Sat)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Tolerance to hypoxia during rest and exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Cardio-respiratory control at rest in normoxia and hypoxia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of patients who increase IgG to above 700 mg/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Average FEV1 during 12 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Weight Standard Deviation Score (SDS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Symptoms change after PEA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in population level cancer screening level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Receptive language skills
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Volume of visceral fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Volume of abdominal subcutaneous fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: joint longitudinal change in rCBF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Dose of propofol required for anaesthetic induction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximally tolerated dose of paclitaxel
Endpoint domain: Adverse events/effects
Primary endpoint: maximally tolerated dose or biologically acceptable dose of TPF
Endpoint domain: Adverse events/effects
Primary endpoint: Change in mean daily number of steps
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Feasibility of decisional aid
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Emergency department utilization
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Emergency Department Visit
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Change of Frequency of Headache
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Severity of Headache
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clindamycin plasma concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serotype-specific antibody concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Sustained response rate of pediatric participants with recurrent or refractory AT/RT
Endpoint domain: Mortality/survival
Primary endpoint: Sustained response rate of pediatric participants with recurrent or refractory MRT
Endpoint domain: Mortality/survival
Primary endpoint: 3-year progression free survival rate
Endpoint domain: Mortality/survival
Primary endpoint: 1-year progression free survival rate
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of participants achieving complete response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of participants with spontaneous regression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of intra-anal HSIL on cytology or histology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Secondary patency of study device at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of adverse events of special interest related to InnAVasc AVG
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in glomerular filtration rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: PTH (Parathyroid Hormone) Adherence
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Time to clinical status improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood Transfusion Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Gestational Diabetes incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Call-to-brain imaging time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average time to measure contrast sensitivity function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average area under the curve for the log contrast sensitivity function (AULCSF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Meibographic severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Interferometric severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of abortive blinks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Pain Score on the Visual Analogue Scale (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak concentration (Cmax) of E3112
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to peak concentration (Tmax) of E3112
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in daily performance of the lymphedema management techniques
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Change in arm girth measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the number of times each patient performed the self-management program
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Cough Frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Target symptom frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in Visual Analogue Pain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Opioid Consumption
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Occurrence of POCD
Endpoint domain: Adverse events/effects
Primary endpoint: Onset of action of tetracaine spray PET500
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of action of tetracaine spray PET500
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Platelet Count Increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Clostridium Difficile Recurrence
Endpoint domain: Adverse events/effects
Primary endpoint: Biosimilarity as measured by absolute neutrophil count (ANC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percent change in recurrence of BV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: occurrence of at least one painful event
Endpoint domain: Adverse events/effects
Primary endpoint: occurrence of treatment discontinuation
Endpoint domain: Adverse events/effects
Primary endpoint: Children Disability Assessment Schedule (DD-CDAS)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Mardird sonographic enthesis index (MASEI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum Tenascin-C concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Percent of Time in Target Blood Glucose Range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean change of 2 minutes walking test (2MWT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of hypotension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Composite of Total Mortality, Disabling Stroke, Serious Bleeding, or Cardiac Arrest
Endpoint domain: Mortality/survival
Primary endpoint: Safety of treatment regimen
Endpoint domain: Adverse events/effects
Primary endpoint: Change in blood pressure over time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Analgesic Efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Histologic Protection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood lipid profile changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Expulsion of stones
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Reduction in the number and size of the stones
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Resilience measured by CD-RISC
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Hospital death prediction
Endpoint domain: Mortality/survival
Primary endpoint: Isokinetic muscle strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Single leg hop test for distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self reported function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: 68Ga-PSMA PET/CT Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ovarian reserve measured by serum anti mullerian hormone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change From Baseline in Glycated Haemoglobin (HbA1c)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in blood lactate level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in base-deficit
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Average Change in Disease Activity Score 28 (DAS 28)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Fulfilling Criteria for a Therapeutic Response According to EULAR Response Criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete Renal Response (CRR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of attempts at intrathecal needle tip placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: reduction in oxygen and ventilation support
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Risk of developing complicated sepsis
Endpoint domain: Mortality/survival
Primary endpoint: Change in quality of life score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: VAS responses at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cardiac output/cardiac input (CO/CI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: mean right arterial pressure (mRAP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Global DNA methylation status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Outcomes of pregnancies following exposure to QIV ID vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Event rate of high-risk adenoma or second primary colorectal cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Executive functions assessed with Memory-based Task Switching
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: GC022 persistence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Performance, usability and ease of use
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Reactogenicity up to 7 days after vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Seroconversion/significant increase in antibody HI titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Blood level concentrations of the drugs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Protocol Compliance
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Perceived Stress Scale (PSS) Scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Cortical Excitability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mild Behavioral Impairment - Checklist (MBI-C)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Kessler Psychological Distress Scale (K10)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Apathy Evaluation Scale (AES-S)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Geriatric Depression Scale - Short Form (GDS-SF)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of Patients With an Objective Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lactate Dehydrogenase (LDH) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with different breast cancer subtypes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Allergy to cephalosporins
Endpoint domain: Adverse events/effects
Primary endpoint: Patient Satisfaction after a teledermoscopy experience
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in progranulin plasma concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects maintaining pure virologic response at HIV 1 RNA threshold of 50 copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: success rate of endotracheal intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: time needed for devices insertion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Early sepsis-associated organ dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of chronic critical illness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Morbid long-term outcomes after sepsis
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Percentage of Participants With Plasma HIV-1 RNA < 50 c/mL at Week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Serious Adverse Events (SAE) and Discontinuation Due to AEs up to Week 24
Endpoint domain: Adverse events/effects
Primary endpoint: Rectal Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Insulin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in peripheral blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Voids/24 Hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in residual concentration of Beta-Lactam antibiotic
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean taste scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean lesion stiffness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in lung function as measured by ventilation defect percentage (VDP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: immunohistochemical markers of prostate pathology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: intraprostate vitamin D metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Quadriceps muscle strength evaluation (Peak Torque)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Peak Plasma Concentration (CMAX) of cephalexin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration versus time curve (AUC) of cephalexin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Facility births
Endpoint domain: Mortality/survival
Primary endpoint: Number of infants developing meconium aspiration syndrome, requiring ECMO or dying
Endpoint domain: Mortality/survival
Primary endpoint: Feasibility of administering a second course of maintenance olaparib
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Changes in HbA1c (%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in levels of P.gingivalis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Area Under the Plasma Concentration-time Curve From Time 0 Extrapolated to Infinite Time (AUCinf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Unbound Area Under The Plasma Concentration-Time Curve From Time 0 Extrapolated To Infinite Time (AUCinf,u)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preservation of endothelium cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ocular Symptomatology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24 hour Area Under the Curve (AUC) of plasma concentrations of DHA and EPA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes